Literature DB >> 1711927

Differential growth inhibition and enhancement of major histocompatibility complex class I antigen expression by interferons in a small-cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant.

S P Cole1, B M Campigotto, J G Johnson, B E Elliott.   

Abstract

Expression of class I and class II major histocompatibility complex antigens on a human small-cell lung cancer cell line and its multidrug-resistant variant was examined before and after exposure to interferon alpha (IFN alpha) and IFN gamma by flow cytometry. Neither IFN alpha nor IFN gamma induced class II antigen expression on the drug-sensitive or resistant cell line. Induction of class I antigen expression along with an inhibition of proliferation was observed in both cell lines after IFN alpha treatment. On the other hand, IFN gamma treatment resulted in growth inhibition and enhancement of class I antigen expression in the sensitive cell line but not the resistant cell line. The differential response of the two cell lines to IFN gamma cannot be directly attributed to the acquisition of drug resistance but it suggests that further investigation of the possibility that drug-sensitive and resistant small-cell lung tumors may respond differently to immunotherapies that include IFN gamma is warranted.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711927     DOI: 10.1007/bf01744948

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Systemic therapy for small-cell lung cancer: old themes replayed, new ones awaited.

Authors:  J Viallet; D C Ihde
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

2.  Modulatory effects of 5-azacytidine, phorbol ester, and retinoic acid on the malignant phenotype of human lung cancer cells.

Authors:  L Olsson; O Behnke; H R Sørensen
Journal:  Int J Cancer       Date:  1985-02-15       Impact factor: 7.396

Review 3.  Perspectives on the role of MHC antigens in normal and malignant cell development.

Authors:  B E Elliott; D A Carlow; A M Rodricks; A Wade
Journal:  Adv Cancer Res       Date:  1989       Impact factor: 6.242

4.  Additive and differential biological activity of alpha-interferon A, difluoromethylornithine, and their combination on established human lung cancer cell lines.

Authors:  G Bepler; D N Carney; M M Nau; A F Gazdar; J D Minna
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

5.  Biological effects of gamma-interferon on human tumor cells: quantity and affinity of cell membrane receptors for gamma-IFN in relation to growth inhibition and induction of HLA-DR expression.

Authors:  U Ucer; H Bartsch; P Scheurich; K Pfizenmaier
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

6.  Conversion of logarithmic channel numbers into relative linear fluorescence intensity.

Authors:  I Schmid; P Schmid; J V Giorgi
Journal:  Cytometry       Date:  1988-11

7.  Paucity of beta 2-microglobulin expression on small cell lung cancer, bronchial carcinoids and certain other neuroendocrine tumors.

Authors:  K Funa; A F Gazdar; J D Minna; R I Linnoila
Journal:  Lab Invest       Date:  1986-08       Impact factor: 5.662

8.  Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.

Authors:  S E Mirski; J H Gerlach; S P Cole
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

10.  Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-Gamma.

Authors:  R Schwartz; F Momburg; G Moldenhauer; B Dörken; V Schirrmacher
Journal:  Int J Cancer       Date:  1985-02-15       Impact factor: 7.396

View more
  2 in total

1.  P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.

Authors:  B Savas; S P Cole; T Tsuruo; H F Pross
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

2.  Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.

Authors:  J Zhang; E H Herman; V J Ferrans
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.